Developmental stuttering: manifestations, treatment and dental implications.

Developmental stuttering (DS) is a disturbance in the normal fluency and time patterning of speech resulting in involuntary repetition, prolongation, or cessation of sound. The scientific literature has implicated the lack of strong left cerebral dominance and abnormal levels of the neurotransmitters dopamine and possibly serotonin in regions of the brain controlling the coordination of language processing and motor activity of the vocal apparatus as possible causative factors in DS. Speech-language therapy is the most common form of treatment, but antipsychotic, antidepressant, and anxiolytic medications may be prescribed for some children and adults with persistent stuttering. These medications may cause xerostomia and adversely interact with certain antibiotics, analgesics, and sedatives routinely used in dentistry. Some people who stutter have sensory-motor and tactile-proprioceptive deficits that impede accurate and timely movements of the mandible, lips, and tongue, necessitating protection of the airway by staff during dental care.

[1]  S. Felsenfeld Finding susceptibility genes for developmental disorders of speech: the long and winding road. , 2002, Journal of communication disorders.

[2]  R. Ingham Brain imaging studies of developmental stuttering. , 2001, Journal of communication disorders.

[3]  K. Heilman,et al.  Anomalous anatomy of speech–language areas in adults with persistent developmental stuttering , 2001, Neurology.

[4]  I. Glick,et al.  Treatment with atypical antipsychotics: new indications and new populations. , 2001, Journal of psychiatric research.

[5]  Richard D. Jones,et al.  Dysfluency and Involuntary Movements: A New Look at Developmental Stuttering , 2001, The International journal of neuroscience.

[6]  M. McClean,et al.  Variations in the relative speeds of orofacial structures with stuttering severity. , 2000, Journal of speech, language, and hearing research : JSLHR.

[7]  S. Kapur,et al.  A positron emission tomography study of silent and oral single word reading in stuttering and nonstuttering adults. , 2000, Journal of speech, language, and hearing research : JSLHR.

[8]  R. Kroll,et al.  Stuttering: an update for physicians. , 2000, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[9]  J. Brady,et al.  Alprazolam, citalopram, and clomipramine for stuttering. , 2000, Journal of clinical psychopharmacology.

[10]  C. Watts,et al.  Timing and intensity variability in the metronomic speech of stuttering and nonstuttering speakers. , 2000, Journal of speech, language, and hearing research : JSLHR.

[11]  E. Yairi,et al.  Early childhood stuttering I: persistency and recovery rates. , 1999, Journal of speech, language, and hearing research : JSLHR.

[12]  K M Heilman,et al.  Developmental stuttering and Parkinson’s disease: the effects of levodopa treatment , 1999, Journal of neurology, neurosurgery, and psychiatry.

[13]  Lisa M. D. Archibald,et al.  The relationship between stuttering severity and kinesthetic acuity for jaw movements in adults who stutter , 1999 .

[14]  D. Haas Adverse drug interactions in dental practice: interactions associated with analgesics, Part III in a series. , 1999, Journal of the American Dental Association.

[15]  J. Montague,et al.  Preliminary information on stuttering characteristics contrasted between African American and white children. , 1999, Journal of communication disorders.

[16]  K Hancock,et al.  Two- to six-year controlled-trial stuttering outcomes for children and adolescents. , 1998, Journal of speech, language, and hearing research : JSLHR.

[17]  S. Grogan,et al.  Outcome measurement in adult stuttering therapy: a self-rating profile. , 1998, International journal of language & communication disorders.

[18]  M. Lawrence,et al.  Stuttering: a brief review. , 1998, American family physician.

[19]  S. Schreiber,et al.  Paroxetine for secondary stuttering: further interaction of serotonin and dopamine. , 1997, The Journal of nervous and mental disease.

[20]  R E Carson,et al.  Altered patterns of cerebral activity during speech and language production in developmental stuttering. An H2(15)O positron emission tomography study. , 1997, Brain : a journal of neurology.

[21]  L. Marangell,et al.  Evaluating the Clinical Significance of Drug Interactions: A Systematic Approach , 1996, Harvard review of psychiatry.

[22]  J. Kalinowski,et al.  Stuttering amelioration at various auditory feedback delays and speech rates. , 1996, European journal of disorders of communication : the journal of the College of Speech and Language Therapists, London.

[23]  M. Hirano,et al.  Activity of intrinsic laryngeal muscles in fluent and disfluent speech. , 1996, Journal of speech and hearing research.

[24]  R. Kroll,et al.  Sertraline in stuttering. , 1995, Journal of clinical psychopharmacology.

[25]  P. Zebrowski The topography of beginning stuttering. , 1995, Journal of communication disorders.

[26]  J. Rapoport,et al.  Fluency changes in persons who stutter following a double blind trial of clomipramine and desipramine. , 1995, Journal of speech and hearing research.

[27]  R. Kroll,et al.  Treatment of stuttering with paroxetine: A case study , 1994 .

[28]  J. Rafuse Early intervention, intensive therapy can help people who stutter. , 1994, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[29]  A Smith,et al.  Neural drive to muscles in stuttering. , 1989, Journal of speech and hearing research.

[30]  K. Bakker Clinical Technologies for the Reduction of Stuttering and Enhancement of Speech Fluency , 1999, Seminars in speech and language.

[31]  M. Yahr,et al.  Sertraline induced parkinsonim. A case report and an in-vivo study of the effect of sertraline on dopamine metabolism , 1998, Journal of Neural Transmission.

[32]  K. Logan,et al.  Parents as partners in the treatment of childhood stuttering. , 1997, Seminars in speech and language.